These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31091334)

  • 1. TCR-induced alteration of primary MHC peptide anchor residue.
    Madura F; Rizkallah PJ; Legut M; Holland CJ; Fuller A; Bulek A; Schauenburg AJ; Trimby A; Hopkins JR; Wells SA; Godkin A; Miles JJ; Sami M; Li Y; Liddy N; Jakobsen BK; Loveridge EJ; Cole DK; Sewell AK
    Eur J Immunol; 2019 Jul; 49(7):1052-1066. PubMed ID: 31091334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.
    Ekeruche-Makinde J; Clement M; Cole DK; Edwards ES; Ladell K; Miles JJ; Matthews KK; Fuller A; Lloyd KA; Madura F; Dolton GM; Pentier J; Lissina A; Gostick E; Baxter TK; Baker BM; Rizkallah PJ; Price DA; Wooldridge L; Sewell AK
    J Biol Chem; 2012 Oct; 287(44):37269-81. PubMed ID: 22952231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.
    Madura F; Rizkallah PJ; Holland CJ; Fuller A; Bulek A; Godkin AJ; Schauenburg AJ; Cole DK; Sewell AK
    Eur J Immunol; 2015 Feb; 45(2):584-91. PubMed ID: 25471691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
    Derré L; Ferber M; Touvrey C; Devevre E; Zoete V; Leimgruber A; Romero P; Michielin O; Lévy F; Speiser DE
    J Immunol; 2007 Dec; 179(11):7635-45. PubMed ID: 18025209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
    Romero P; Gervois N; Schneider J; Escobar P; Valmori D; Pannetier C; Steinle A; Wolfel T; Lienard D; Brichard V; van Pel A; Jotereau F; Cerottini JC
    J Immunol; 1997 Sep; 159(5):2366-74. PubMed ID: 9278327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
    Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
    J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
    Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
    J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.
    Borbulevych OY; Santhanagopolan SM; Hossain M; Baker BM
    J Immunol; 2011 Sep; 187(5):2453-63. PubMed ID: 21795600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
    Wang Z; Turner R; Baker BM; Biddison WE
    J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.
    Denkberg G; Cohen CJ; Lev A; Chames P; Hoogenboom HR; Reiter Y
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9421-6. PubMed ID: 12093904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
    Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.
    Smith SN; Sommermeyer D; Piepenbrink KH; Blevins SJ; Bernhard H; Uckert W; Baker BM; Kranz DM
    J Mol Biol; 2013 Nov; 425(22):4496-507. PubMed ID: 23954306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for clonal diversity of the human T-cell response to a dominant influenza virus epitope.
    Yang X; Chen G; Weng NP; Mariuzza RA
    J Biol Chem; 2017 Nov; 292(45):18618-18627. PubMed ID: 28931605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell receptors: tugging on the anchor for a tighter hold on the tumor-associated peptide.
    Dyson J
    Eur J Immunol; 2015 Feb; 45(2):380-2. PubMed ID: 25581444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.